Strategy

Developing differentiated therapies capable of addressing the unmet needs in challenging acute pain and inflammatory disorders.

Many people in pain have been left behind by the current standard of care. Treatment options are limited, which forces many to resort to less effective therapy, use drugs with significant trade-offs, or live in pain.

Tremeau’s strategy is to identify well-defined conditions where our clinically differentiated products can address important unmet needs.

Venn diagram: pain responsive to an anti-inflammatory; GI or hemorrhagic concern limiting traditional NSAID use; patients resorting to inadequate pain treatment. Shaded overlaps show appropriate use for a COXIB.

Our lead, investigational, clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic

TRM-201 (rofecoxib) is a re-engineered, patented COX-2 selective NSAID formulation designed for improved efficacy and safety for painful conditions.